Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Anastrozole in Healthy Chinese Volunteers
NCT04438733Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anastrozole in breast cancer (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum Plasma Concentration at 72 hours, Area Under the Curve from time 0 to last measurable concentration at 72 hours and 2 more. Status: unknown.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04438733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438733.